The future of Johnson & Johnson's cancer blockbuster Zytiga is in doubt, after a US patent ruling has opened the door to generic competitors. Johnson & Johnson’s Q4 results were hit by a one-off ...

The EMA’s human medicines committee has recommended approval for Akeega, a fixed-dose combination of J&J’s PARP drug Zejula (niraparib) and androgen inhibitor Zytiga (abiraterone acetate), in ...

A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.

Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

The sales growth was partially dampened by lower sales of Stelara, Imbruvica and generic/biosimilar competition to drugs like Zytiga and Remicade. Sales of blockbuster multiple myeloma medicine ...

J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector. The FDA granted approval to AstraZeneca AZN and partner Daiichi’s novel TROP2 ...

Citi reaffirmed its Buy rating and $13.00 price target for ORIC Pharmaceuticals (NASDAQ:ORIC), whose stock currently trades at $10.15. The company has shown strong momentum with a 25.77% year-to-date ...

周二，花旗重申了对ORIC制药（NASDAQ:ORIC）的买入评级和13.00美元的目标价。该公司股票目前交易价格为10.15美元。尽管近期市场波动，该公司年初至今仍录得25.77%的强劲回报。该机构预计，ORIC的股价将在2月13日显著上涨，届时辉瑞（PFE）的ASCO ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.